GLP-1 receptor
Supports glucose-dependent insulin signalling, suppresses inappropriate glucagon release and contributes to satiety and slower gastric emptying.
NXP / 02
Research profile
Retatrutide
30MGTriple-receptor agonist research peptide
Retatrutide (LY3437943) is an investigational peptide engineered to activate the GIP, GLP-1 and glucagon receptors within one molecule. It is studied as a coordinated metabolic signal rather than a single-pathway agonist.
Scientific context
What it does.
In controlled research, retatrutide is used to examine appetite signalling, glucose regulation, gastric emptying, lipid handling and energy expenditure. Reported human outcomes belong to clinical trials and must not be interpreted as approval, a treatment claim or a prediction for an individual.
Mechanism map
How the research
model works.
GIP receptor
Adds a second incretin signal involved in post-meal insulin response and metabolic substrate handling.
Glucagon receptor
Introduces a counterbalancing pathway associated with hepatic energy turnover and lipid metabolism; the combined pharmacology is the central research question.
Study design
Research pairing
options.
These are experimental design concepts—not recommendations for human use, co-administration or dosing.
NAD+ 500MG
Useful in separate or factorial study arms exploring redox state, mitochondrial metabolism and downstream cellular energetics.
Treat as a complementary endpoint strategy—not evidence that co-administration is safe or beneficial.Single-pathway comparator
A GLP-1 or GIP/GLP-1 comparator arm can help isolate the contribution of triple-receptor activity.
Avoid combining overlapping incretin agonists in the same experimental subject without an approved protocol and safety review.Unstacked control
Retatrutide alone is the cleanest way to attribute receptor, biomarker and tolerability observations to the test article.
The primary recommended research design is a controlled single-variable arm.Interpretation controls
Important
limitations.
- Investigational and not represented by NexPep as approved for human use.
- Overlapping metabolic agonists can create confounded results and potentially additive biological effects.
- Identity, purity, concentration and receptor activity should be verified before experimental interpretation.
Evidence trail